biotech insider buying
biotech insider buying Articles
The past week brought some huge insider share purchases, including a contrarian buy at an e-commerce platform operator and another at a troubled satellite provider.
Published:
Warren Buffett again boosted his stake in the newly independent Sirius XM. A biotech IPO prompted huge insider buying as well.
Published:
Warren Buffett again boosted his stake in the newly independent Sirius XM. Biotech stocks continue to prompt notable insider buying as well.
Published:
Warren Buffett recently boosted his stake in the newly independent Sirius XM. Biotech initial public offerings in the past week also prompted some huge insider buying.
Published:
Public offerings of stock and activist investor activity prompted some huge insider buying at an entertainment company, an airline, biotechs, and more.
Published:
A public offering of shares this past week prompted a huge purchase from a beneficial owner. Meanwhile, a couple of repeat buyers further boosted their stakes as well.
Published:
IPOs at three biotechs last week tempted insiders to make huge purchases of shares. This effect spilled over into buying at a couple of other biotechs as well.
Published:
Though insider buying has slowed to a trickle in the past two weeks, two CEOs and two beneficial owners made notable purchases.
Published:
Top carmaker Stellantis boosted its stake in an aircraft maker last week, and biotech and energy stocks saw notable insider buying too.
Published:
A renowned billionaire investor, a French energy giant, and other insiders were scooping up shares of these five stocks as the second quarter began.
Published:
Warren Buffett boosts his stake in this tracking stock again, plus notable insider buying from an NFL team owner and a new CEO.
Published:
Public offerings of stock tempted some insider buying, and one insider stepped up to support a struggling online delivery service provider.
Published:
A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted insider buying at some biotech companies.
Published: